Multi-color CD34 + progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 974-981

  Tang, Guilin ^a   Jorgensen, Jeffrey L ^a   Zhou, Yi ^a   Hu, Ying ^a   Kersh, Marian ^a   Garcia Manero, Guillermo ^a   Jeffrey Medeiros, L ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CD34 + progenitors; Cytopenia; Multi color flow cytometry; Myelodysplastic syndromes; Myelomonocytic cells; Therapy related

Indexed keywords

ANTINEOPLASTIC AGENT; CD123 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR;

5Q- SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CHILD; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC ACCURACY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MONOCYTE MACROPHAGE PRECURSOR CELL; MORPHOLOGY; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; REPRODUCIBILITY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLOR; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; PANCYTOPENIA; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDIES AS TOPIC;

EID: 84862578497     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.001     Document Type: Article

References (29)

1. Ok C.Y., Medeiros L.J., Hu Y., Bueso-Ramos C.E., Wang S.A. Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res 2011, 35(12):1605-1610.
2. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology 2007, 74(2):97-114.
3. Brunning R.D., Germing U., Le Beau M.M., Porwit A., Baumann I., Vardiman J.W., Hellstrom-Lindberg E. Myelodysplastic syndromes/neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissue 2008, 88-107. IARC, Lyon. 4th ed. S.H. Swerdlow, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
4. Kussick S.J., Fromm J.R., Rossini A., Li Y., Chang A., Norwood T.H., et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005, 124(2):170-181.
5. Stachurski D., Smith B.R., Pozdnyakova O., Andersen M., Xiao Z., Raza A., et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008, 32(2):215-224.
6. Stetler-Stevenson M., Arthur D.C., Jabbour N., Xie X.Y., Molldrem J., Barrett A.J., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001, 98(4):979-987.
7. Truong F., Smith B.R., Stachurski D., Cerny J., Medeiros L.J., Woda B.A., et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 2009, 33(8):1039-1046.
8. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102(1):394-403.
9. van de Loosdrecht A.A., Westers T.M., Westra A.H., Drager A.M., van der Velden V.H., Ossenkoppele G.J. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008, 111(3):1067-1077.
10. van de Loosdrecht A.A., Alhan C., Bene M.C., Della Porta M.G., Drager A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94(8):1124-1134.
11. + cells in low-grade myelodysplastic syndromes. Blood 2006, 108(3):1037-1044.
12. Ogata K., Nakamura K., Yokose N., Tamura H., Tachibana M., Taniguchi O., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002, 100(12):3887-3896.
13. Ogata K., Della Porta M.G., Malcovati L., Picone C., Yokose N., Matsuda A., et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 2009, 94(8):1066-1074.
14. Harrington A., Olteanu H., Kroft S. The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. Am J Clin Pathol 2010, 134(5):749-761.
15. Xu F., Li X., Wu L., He Q., Zhang Z., Chang C. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol 2010, 149(4):587-597.
16. + hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008, 22(6):1175-1183.
17. Kern W., Haferlach C., Schnittger S., Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010, 116(19):4549-4563.
18. Pirruccello S.J., Young K.H., Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 2006, 125(6):884-894.
19. Zhou Y., Tang G., Medeiros L.J., McDonnell T.J., Keating M.J., Wierda W.G., et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2011, [epub].
20. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31(6):727-736.
21. Beutler E., Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?. Blood 2006, 107(5):1747-1750.
22. Wang S.A., Tang G., Fadare O., Hao S., Raza A., Woda B.A., et al. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol 2008, 21(11):1394-1402.
23. Westers T.M., Alhan C., Chamuleau M.E., van der Vorst M.J., Eeltink C., Ossenkoppele G.J., et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010, 115(9):1779-1784.
24. Sternberg A., Killick S., Littlewood T., Hatton C., Peniket A., Seidl T., et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005, 106(9):2982-2991.
25. McKenna R.W., Washington L.T., Aquino D.B., Picker L.J., Kroft S.H. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001, 98(8):2498-2507.
26. + cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006, 108(1):337-345.
27. Maftoun-Banankhah S., Maleki A., Karandikar N.J., Arbini A.A., Fuda F.S., Wang H.Y., et al. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol 2008, 129(2):300-308.
28. Micheva I., Thanopoulou E., Michalopoulou S., Karakantza M., Kouraklis-Symeonidis A., Mouzaki A., et al. Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes. Clin Immunol 2004, 113(3):310-317.
29. Mufti G.J., Bennett J.M., Goasguen J., Bain B.J., Baumann I., Brunning R., et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008, 93(11):1712-1717.